CAR-PRISM

Myeloma Cancer

CAR-PRISM

Manufactured by: Janssen Biotech, Inc. and Legend Biotech USA, Inc.
Product name: CARVYKTI® (ciltacabtagene autoleucel)

About the CAR-PRISM Trial

The CAR-PRISM study explored the use of Ciltacabtagene Autoleucel (cilta-cel)—a BCMA-targeting CAR-T therapy—for patients with high-risk smoldering multiple myeloma (HR-SMM), marking a bold shift in CAR-T use toward earlier disease stages. In this early-phase study, six participants were treated, excluding those with >40% plasma cells and without a control group. Results presented at ASH 2024 demonstrated 100% complete response (CR) and MRD negativity at 10⁻⁶, with no dose-limiting toxicities or high-grade cytokine release syndrome (CRS). Despite these impressive efficacy signals, several key opinion leaders, including Dr. Vinay Prasad and Dr. Aaron Goodman, raised ethical concerns about the study’s design—particularly the absence of a control arm and potential risks in treating otherwise asymptomatic patients. While the therapy appears safe and effective in this small cohort, the lack of long-term data and questions about overtreatment in HR-SMM warrant further scrutiny before broader application.

Table of Contents

Major Presentations and Milestones

CAR-PRISM Trial design, results, and conclusions

CAR-PRISM Sentiments and Criticisms

CAR-PRISM Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

CAR-PRISM Trial: Major Presentations and Milestones

Primary speakers driving the story

ASH 2024 abstract release (Nov 2024): Early attention to CAR-PRISM as a CAR-T strategy in high-risk smoldering myeloma.

Source: https://x.com/Abdallah81MD/status/1860570028015280226

ASH 2024 oral presentation cycle (Dec 2024): Broader discussion of eligibility definition, safety signals, and depth of response in a very small cohort.

Source: https://x.com/MM_Hub/status/1866961368001515582

CAR-PRISM Trial Design, Results, and Conclusions

Trial Design (as described in tweet text):

  • Study: CAR-PRISM study using ciltacabtagene autoleucel (cilta-cel) in high-risk smoldering multiple myeloma (precursor myeloma).
  • Enrollment (as stated by Abdallah): “6 pts were enrolled/Cilta-Cel to treat High risk smoldering myeloma…”
  • Eligibility nuance (as stated by Al-Hadidi): “Pts with PC>40% were excluded” and he notes missing baseline disease burden details in the presentation (“No data on M protein levels, FLC or PC% provided”).

Sources:

Key Results (as stated in tweet text):

  • Safety (Al-Hadidi): “Safety data presented were limited: 2 G2 CRS (one-third of patients), 1 pt with facial palsy (17%) …”
  • Early efficacy/depth (MM_Hub summary): “There were no DLTs observed, no GR≥3 CRS, ≥CR 100%, MRD x10^-6 100%. Longer FU is required to determine durability…”

Source: https://x.com/MM_Hub/status/1866961368001515582

Safety detail and eligibility critique (KOL thread):

Source: https://x.com/HadidiSamer/status/1866284015638196596

Key Conclusions:

  • CAR-PRISM is being discussed as demonstrating very deep responses in an extremely small high-risk smoldering cohort treated with cilta-cel, with early safety signals including grade 2 CRS and cranial neuropathy/facial palsy reported in the meeting discussion.
  • Multiple commentators emphasize the need for longer follow-up and careful patient selection/definition of “high risk” given the toxicity and cost profile of CAR-T in a precursor condition.

CAR-PRISM Sentiments and Criticisms (Themes)

Theme 1 — Ethical concerns and risk-benefit balance in precursor disease

  • Goodman: “You can you be completely healthy, get a lab test checked you never needed, and end up receiving a toxic million dollar therapy with risks of secondary cancers and long term neurologic side effects.”

Source: https://x.com/AaronGoodman33/status/1844470329714106595

Source: https://x.com/AaronGoodman33/status/1844470329714106595

Theme 2 — Trial design criticism (control arm / ethics framing)

  • Prasad: “A reminder that this trial ongoing at @DanaFarber is unethical… More than half these pts won't progress in 3 yrs & researchers are giving a product with 3% risk of parkinsons… Worst: no control arm… This is reckless experimentation”

Source: https://x.com/VPrasadMDMPH/status/1860119611431432418

Source: https://x.com/VPrasadMDMPH/status/1860119611431432418

Theme 3 — Risk definition and reporting transparency

  • Al-Hadidi: “No data on M protein levels, FLC or PC% provided” and “Safety data presented were limited…” (in the context of defining high-risk SMM and interpreting a 6-patient cohort).

Source: https://x.com/HadidiSamer/status/1866284015638196596

CAR-PRISM Temporal Sentiment Arc

Oct 2024: early public skepticism about overtreatment risk

Nov 2024 (ASH abstract release): awareness + early framing

Dec 2024 (ASH24 oral): early results dissemination and “need longer follow-up” emphasis

CAR-PRISM Professional Resources